Ben-Fillippo Krippendorff
Ben-Fillippo Krippendorff
Afiliación desconocida
Dirección de correo verificada de
Citado por
Citado por
G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells
KIE McLuckie, M Di Antonio, H Zecchini, J Xian, C Caldas, ...
Journal of the American Chemical Society 135 (26), 9640-9643, 2013
Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values
BF Krippendorff, R Neuhaus, P Lienau, A Reichel, W Huisinga
Journal of biomolecular screening 14 (8), 913-923, 2009
Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis
BF Krippendorff, K Kuester, C Kloft, W Huisinga
Journal of pharmacokinetics and pharmacodynamics 36 (3), 239-260, 2009
Optimizing classification of drug-drug interaction potential for CYP450 isoenzyme inhibition assays in early drug discovery
BF Krippendorff, P Lienau, A Reichel, W Huisinga
Journal of biomolecular screening 12 (1), 92-99, 2007
Influence of molecular size on tissue distribution of antibody fragments
Z Li, BF Krippendorff, S Sharma, AC Walz, T Lavé, DK Shah
MAbs 8 (1), 113-119, 2016
Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
Y Lin, FM Richards, BF Krippendorff, JL Bramhall, JA Harrington, ...
British journal of cancer 107 (10), 1692-1701, 2012
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer
A Courtin, FM Richards, TE Bapiro, JL Bramhall, A Neesse, N Cook, ...
PloS one 8 (6), e67330, 2013
Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy
F Bauss, M Lechmann, BF Krippendorff, R Staack, F Herting, M Festag, ...
Molecular oncology 10 (8), 1317-1329, 2016
Quantification of IgG monoclonal antibody clearance in tissues
MJ Eigenmann, L Fronton, HP Grimm, MB Otteneder, BF Krippendorff
MAbs 9 (6), 1007-1015, 2017
Predicting the F (ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling
BF Krippendorff, DA Oyarzún, W Huisinga
Journal of pharmacokinetics and pharmacodynamics 39 (2), 125-139, 2012
Interstitial IgG antibody pharmacokinetics assessed by combined in vivo‐and physiologically‐based pharmacokinetic modelling approaches
MJ Eigenmann, TV Karlsen, BF Krippendorff, O Tenstad, L Fronton, ...
The Journal of physiology 595 (24), 7311-7330, 2017
Capacity limits of asialoglycoprotein receptor-mediated liver targeting
C Bon, T Hofer, A Bousquet-Mélou, MR Davies, BF Krippendorff
MAbs 9 (8), 1360-1369, 2017
A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer
G Kollmorgen, K Palme, A Seidl, S Scheiblich, F Birzele, S Wilson, ...
Scientific reports 7 (1), 1-13, 2017
The EGFR demonstrates linear signal transmission
DA Oyarzún, JL Bramhall, F López-Caamal, FM Richards, DI Jodrell, ...
Integrative biology 6 (8), 736-742, 2014
Influence of Molecular size on the clearance of antibody fragments
Z Li, BF Krippendorff, DK Shah
Pharmaceutical research 34 (10), 2131-2141, 2017
Hybrid stochastic-deterministic approaches for simulation and analysis of biochemical reaction networks
S Menz
Ligand accumulation counteracts therapeutic inhibition of receptor systems
BF Krippendorff, D Oyarzún, W Huisinga
RG7787-a novel de-immunized PE based fusion protein for therapy of mesothelin-positive solid tumors
G Niederfellner, F Bauss, S Imhof-Jung, F Hesse, S Kronenberg, R Staak, ...
Cancer Research 74 (19 Supplement), 4510-4510, 2014
Target‐Driven Pharmacokinetics of Biotherapeutics
W Huisinga, S Fuhrmann, L Fronton, BF Krippendorff
Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and …, 2010
Integrating cell-level kinetic modeling into the optimization of cancer therapeutics
BF Krippendorff
National University of Ireland Maynooth, 2010
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20